title: Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation.
abstract: There has been little exploration of major biologic regulators of cerebral development in autism. In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5). Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children. In 99% of children with autism and 97% with mental retardation, levels of at least one of these substances exceeded those of all control children. Concentrations were similar in subgroups of the autistic spectrum (core syndrome with or without mental retardation, other autistic spectrum disorders with or without mental retardation) and in the presence or absence of a history of regression. Among children with mental retardation, concentrations did not differ by severity or known cause (n = 11, including 4 with Down syndrome). Concentrations of measured substances were similar in children with CP as compared with control subjects. SP, PACAP, NGF, and NT3 were not different by diagnostic group. No measured analyte distinguished children with autism from children with mental retardation alone. In autism and in a heterogeneous group of disorders of cognitive function, overexpression of certain neuropeptides and neurotrophins was observed in peripheral blood drawn in the first days of life.
authors.affiliation: National Institute of Neurological Diseases and Stroke, Bethesda, MD 20892-1447, USA. knelson@helix.nih.gov
authors.forename: K B
authors.initials: KB
authors.lastname: Nelson
authors.forename: J K
authors.initials: JK
authors.lastname: Grether
authors.forename: L A
authors.initials: LA
authors.lastname: Croen
authors.forename: J M
authors.initials: JM
authors.lastname: Dambrosia
authors.forename: B F
authors.initials: BF
authors.lastname: Dickens
authors.forename: L L
authors.initials: LL
authors.lastname: Jelliffe
authors.forename: R L
authors.initials: RL
authors.lastname: Hansen
authors.forename: T M
authors.initials: TM
authors.lastname: Phillips
mesh_terms: D001321:Autistic Disorder / Q000097:blood*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000097:blood*; D008297:Male; D009414:Nerve Growth Factors / Q000097:blood*; D009479:Neuropeptides / Q000097:blood*
chemical_list: D009414:Nerve Growth Factors; D009479:Neuropeptides